As Figures 5C–D show, combination treatment expressed better tumor growth inhibition (about one-fold) when compared with single OHP treatment or single FHL3-knockdown treatment in HGC subcutaneous tumor model (P < 0.001). The gene discussed is FHL3; the disease is neoplasm.